Evidence map›Paper›PMID 25077923›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014

The prognostic value of HER-2/neu overexpression in colorectal cancer: evidence from 16 studies.

Sheng-Wen Wu, Cong-Chao Ma, Yu Yang

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Association of HER2 codon 655 polymorphism with ovarian cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sheng-Wen WuDepartment of General surgery, The Affiliated Jianhu Hospital of Nantong University, Jianhu People's Hospital, Jianhu, 224700, Jiangsu Province, China.
Cong-Chao Ma
Yu Yang
Nantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human epidermal growth factor receptor (HER-2/neu) plays an important role in the progression of several types of cancer. Numerous studies examining the relationship between HER-2 overexpression and prognostic impact in patients with colorectal cancer have yielded inconclusive results. We therefore conducted a meta-analysis to provide a comprehensive evaluation of the prognostic value of HER-2 expression on the survival, which compared the positive and negative expressions of HER-2 in patients of the available studies. Hazard ratios (HRs) and their corresponding 95% confidence intervals (95% CIs) were pooled in terms of disease-specific or overall survival. A detailed search was made in PubMed for relevant original articles published in English. Finally, a total of 18 studies with 16 colorectal cancer patients were involved. Overexpression of HER-2 was negatively related to survival in colorectal cancer patients with the pooled HR of 1.05 (95% CI 0.78-1.31, P = 0.000). In conclusion, the finding from this present meta-analysis suggested that HER-2 overexpression was not related to poor prognostic of colorectal cancer.

Indexed as

AgedCase-Control StudiesColorectal NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansMeta-Analysis as TopicMiddle AgedPrognosisSurvival RateERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID25077923
OpenAlexW2031915299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.